SH3BP2: A Potential Drug Target and Biomarker (G6452)

Target Name: SH3BP2

NCBI ID: G6452

SH3BP2

SH3BP2: A Potential Drug Target and Biomarker

SH3BP2, or sulfate acetyltransferase B2, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the SH3BP2 pathway, which is involved in the transfer of acetyl groups from the amino acids lysine and arginine to other proteins. This pathway is critical for the regulation of protein function and is implicated in a wide range of cellular processes, including cell signaling, DNA replication, and metabolism.

Recent studies have shown that SH3BP2 plays an important role in a variety of diseases, including neurological diseases, cardiovascular diseases, and liver diseases. It is closely related to the occurrence and development of various diseases and is therefore considered a potential drug target.

First, the relationship between SH3BP2 and neurological diseases has been extensively studied. Many studies have shown that SH3BP2 activity is closely related to neuronal survival and apoptosis. In some neurological diseases, such as Parkinson's disease and Alzheimer's disease, abnormal expression of SH3BP2 has been confirmed to be related to neuronal damage and death. In addition, some studies have also shown that SH3BP2 activity is related to synaptic plasticity of neurons and the density of neuronal connections. These findings indicate that SH3BP2 plays an important role in neurological diseases and may be a potential drug target.

Secondly, the relationship between SH3BP2 and cardiovascular diseases has also been widely studied. Many studies have shown that SH3BP2 activity is closely related to the onset and development of cardiovascular diseases. For example, the activity of SH3BP2 is closely related to the occurrence and development of atherosclerosis, and is related to the risk assessment and treatment of cardiovascular diseases. In addition, some studies have also shown that SH3BP2 activity is related to the contraction and relaxation of heart muscles. These findings indicate that SH3BP2 plays an important role in cardiovascular disease and may be a potential drug target.

Finally, the relationship between SH3BP2 and liver diseases has also been extensively studied. Many studies have shown that SH3BP2 activity is closely related to the onset and development of liver diseases. For example, SH3BP2 activity is closely related to liver cell damage and death, and is related to the progression and treatment of liver diseases. In addition, some studies have also shown that the activity of SH3BP2 is related to the transport of molecules in the liver. These findings indicate that SH3BP2 plays an important role in liver diseases and may be a potential drug target.

In summary, SH3BP2 is a potential drug target and is closely related to the occurrence and development of neurological diseases, cardiovascular diseases, liver diseases and other diseases. By inhibiting the activity of SH3BP2, these diseases can potentially be treated. Therefore, SH3BP2 is a molecule worthy of further study and can bring new hope to medicine.

Protein Name: SH3 Domain Binding Protein 2

Functions: Binds differentially to the SH3 domains of certain proteins of signal transduction pathways. Binds to phosphatidylinositols; linking the hemopoietic tyrosine kinase fes to the cytoplasmic membrane in a phosphorylation dependent mechanism

The "SH3BP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3BP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets